Clinically, EGFR ex20ins mutations are often enriched in patients with adenocarcinoma histology and never-smoking status and are associated with poorer outcomes compared with tumors harboring classical sensitizing EGFR mutations (1, 7). The gene discussed is EGFR; the disease is adenocarcinoma.